Stryker shares tumble despite strong Q2 results and raised guidance
Jason A. Okazaki, CEO and President of Assembly Biosciences, Inc. (NASDAQ:ASMB), has recently sold a portion of his holdings in the company. According to a recent SEC filing, Okazaki sold 355 shares of common stock on March 31, 2025, at a weighted average price of $9.8481 per share. This sale, totaling approximately $3,496, was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units. The transaction comes as ASMB trades near its 52-week low of $9.56, having declined over 16% in the past week alone. InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $31 to $36.
In addition to the sale, Okazaki acquired 71,100 stock options, which grant him the right to buy shares at a conversion price of $10.62. These options, which were granted on March 29, 2025, will vest over a period of four years, assuming continuous service.
Following these transactions, Okazaki holds 14,757 shares of common stock directly. The transactions reflect routine financial management, as the sale was mandated by an administrative rule for tax purposes rather than a discretionary decision by Okazaki.
In other recent news, Assembly Biosciences has initiated a Phase 1a clinical trial for ABI-6250, an investigational oral therapy for chronic hepatitis delta virus (HDV) infection. The trial will assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers, with results expected in Q3 2025. In parallel, Assembly Biosciences is advancing its herpes treatment, ABI-1179, into the next trial phase following positive interim results from its Phase 1a study. The upcoming Phase 1b study will further explore the drug’s safety and antiviral activity in participants with recurrent genital herpes.
Additionally, Assembly Biosciences has extended its sublease for office and laboratory space in South San Francisco through September 2029. The agreement includes escalating base rent payments and a right of first refusal for additional space. These developments highlight Assembly Biosciences’ ongoing efforts in drug development and operational expansion. The company continues to focus on treatments for serious viral diseases, with several investigational products in various stages of clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.